TB-500 for Sale — Buyer Guide 2026
TB-500 (thymosin beta-4 fragment) is a research peptide studied for wound-healing and tissue-repair properties in preclinical models. Before buying, verify batch-linked third-party COAs confirming ≥98% purity, research-use-only framing, transparent third-party testing from recognized labs, and no therapeutic claims on the vendor page.
Midwest Peptide
10% off with code SQUARETABLE10 · 30-day cookie · 10% recurring commission
What TB-500 Is
TB-500 is the synthetic acetate salt of thymosin beta-4, a 43-amino-acid peptide present naturally in human and animal cells. It was first isolated from calf thymus in the 1960s and has been studied extensively in preclinical research for its roles in cell migration, blood vessel formation, actin regulation, and wound-healing pathways. In the research market, it is one of the most widely available peptides — which also makes it one of the most commonly counterfeited. The disconnect between high demand and limited pharmaceutical-grade supply means research-market quality varies dramatically between vendors.Regulatory Status and Research-Market Position
TB-500 (thymosin beta-4) is not FDA-approved for any indication. An injectable formulation of the native peptide (reparixin-related) has been studied in clinical trials for cardiac repair and ophthalmic applications under investigational new drug applications, but these are distinct from research-market TB-500 acetate. Research-vendor TB-500 is sold strictly as a chemical for laboratory study — not as an investigational drug or a therapeutic product. Vendors that conflate clinical-trial status with their products are misleading buyers.5 Checks Before Buying
- Third-party, batch-linked COA: Independent lab testing with a batch number matching the product listing. Self-issued COAs or generic test results are not sufficient evidence of quality for a peptide this commonly counterfeited.
- HPLC data with chromatogram: Visual chromatograms showing a clean single peak at the expected retention time. MS data confirming molecular weight is a strong bonus. Reject vendors who provide only a purity percentage without supporting analytical data.
- Research-use-only compliance: Vendors must clearly position the product for research and avoid any health-outcome framing, dosing language, or before-and-after imagery. Regulatory agencies have issued warnings to vendors crossing this line.
- Shipping and storage transparency: Peptides require proper storage conditions. Reputable vendors state how products are stored (temperature-controlled, desiccated, lyophilized format) and shipped (cold packs when needed, insulated packaging).
- Documentation recency: Test reports for current inventory should be within the last 6-12 months. Older reports may not reflect the batch you would receive — inventory turnover matters.
Vendor Evaluation Table
| Vendor | COA / Testing Signal | Transparency Score | Risk Level |
|---|---|---|---|
| Peptide Partners | Four-lab roster + contaminant-panel archive | 78/100 · S tier | Low |
| OROS Research | ISO 17025 lab + per-lot testing posture | 75/100 · S tier | Low |
| Pure Peptides | Product-level MZ Biolabs COAs | 73/100 · A tier | Low |
| Crush Research | Four named labs + multi-vial methodology claim | 70/100 · A tier | Medium |
| Kimera Chems | Live COA archive + ISO 17025 lab partner signal | 70/100 · A tier | Medium |
| Elite Research USA | Per-product COAs + three named labs | 70/100 · A tier | Medium |
Seed evaluation from Matt's Reptides intake. Each claim should be re-verified against primary sources before final publication.
Red Flags That Mean Walk Away
Walk away from any TB-500 vendor that: markets with before-and-after recovery photos or healing testimonials, recommends dosing or administration routes in any format, sells through social media DMs or peer marketplaces like eBay or Facebook groups, provides no COA or only a generic certificate without batch matching, uses stock photography of vials without visible batch labels, or prices dramatically below the peer average. TB-500 is frequently counterfeited — low price is the most common counterfeit signal. Vendors offering 'discount TB-500' without equally transparent documentation should be assumed to sell counterfeit or adulterated product.Published Research Context
TB-500/thymosin beta-4 has been the subject of hundreds of published studies indexed in PubMed. Research has explored its role in angiogenesis, cardiac repair, corneal wound healing, and neuroprotection in animal models. These studies used specifically characterized thymosin beta-4 preparations — not research-vendor TB-500 acetate. The presence of published research on thymosin beta-4 does not validate any particular vendor's product. Always distinguish between peer-reviewed research findings and the quality of commercially available research peptides. For context, see the thymosin beta-4 records in PubMed and ClinicalTrials.gov for any registered clinical investigations.Frequently Asked Questions
What is the difference between TB-500 and BPC-157?
They are entirely different peptides with different mechanisms. TB-500 is thymosin beta-4, a 43-amino-acid peptide involved in cell migration, angiogenesis, and actin regulation. BPC-157 is a body-protective compound derived from a human gastric juice protein sequence. Both have been studied in preclinical wound-healing research, but they are distinct molecules with separate testing profiles, mechanisms, and research applications.
How can I tell if a TB-500 COA is legitimate?
Legitimate COAs show: an independent laboratory header with verifiable contact information, a batch/lot number matching the product, an HPLC chromatogram showing a clean peak, date of analysis, and analyst signature or digital verification. You should be able to independently confirm the laboratory exists by a web search. Generic COAs without lab details or batch numbers are not meaningful.
Is TB-500 commonly counterfeited?
Yes. TB-500's popularity in the research market makes it a frequent target for counterfeiters. Products sold below market average price, through peer marketplaces, or without independently verifiable third-party testing should be presumed counterfeit until proven otherwise. The counterfeit rate is high enough that vendor diligence is essential.
Has TB-500 been FDA-approved?
No. Thymosin beta-4 (the native peptide that TB-500 is modeled after) has not received FDA approval as a therapeutic product. Some investigational formulations have been studied in clinical trials under IND applications, but these are not the same as research-market TB-500 acetate sold by peptide vendors. Research products carry no FDA endorsement.
What purity level should I expect from research vendors?
Reputable research-vendor TB-500 typically tests at ≥98% purity by HPLC. Products claiming higher purity should provide correspondingly stronger analytical evidence — both chromatograms and MS data. Anything below 97% should trigger additional third-party verification before purchase.
Related Pages
Peptide Vendor Rankings → · How to Read a COA → · Our Evaluation Methodology →
Verification Notes for TB-500 for Sale — Buyer Guide 2026
This file is reviewed as part of the The Peptide Reviewer documentation system, which means the page is not judged by headline confidence alone. The desk checks whether the claim has a date, whether the source can be opened by a reader, whether commercial language is separated from editorial scoring, and whether a medical or regulatory boundary is visible before the reader reaches any vendor context.
For tb 500 for sale, the practical standard is source literacy. A reader should be able to trace the page back to primary records, compare those records with the current vendor or compound claim, and see what the page does not prove. If a vendor changes a COA, removes a lab report, edits a product page, or adds health-outcome language after this review date, the conclusion can change. That is why this publication keeps source dates, correction rules, and reviewer scope close to the article body instead of hiding them in a footer.
The editorial team uses the same baseline checks across peptide vendor reviews, compound explainers, comparison pages, trust pages, and author pages. First, the page must identify the entity or topic clearly. Second, it must point readers toward primary-source verification. Third, it must avoid personal-use instructions and medical recommendations. Fourth, it must disclose when affiliate economics could exist and state that payment does not change scoring, inclusion, risk labels, or rank order.
When the page discusses a compound, the review separates published research context from research-market product claims. Published studies, trial records, or regulatory documents can describe a molecule, but they do not verify a private vendor batch. When the page discusses a vendor, the review separates a vendor's public marketing from documentation that can be checked, including batch-linked certificates, lab identity, source dates, claims language, and correction history.
Readers should treat this file as an audit trail, not a shortcut. The safest way to use it is to open the listed sources, confirm the current date on the vendor or regulatory record, and compare that source with the page summary. If the source and summary disagree, the source wins until the page is corrected. If the source cannot be found, the claim should be treated as unverified.
This added review note also gives crawlers and readers the same context that the editors use internally: what kind of evidence matters, which trust pages govern the file, who owns the review boundary, and where a correction should start. That matters most on author, policy, and directory pages because those pages can look thin even when they carry important E-E-A-T signals. The added context makes the page auditable without turning it into a new article.
- PubMed for published biomedical literature and review context.
- ClinicalTrials.gov for registered trial status and study records.
- FDA for approval status, warning letters, labeling, and regulatory context.
Frequently Asked Questions
How should I verify this page?
Start with the date, then open the primary source rather than relying on a summary. For medical or regulatory context, check PubMed, ClinicalTrials.gov, and FDA records. For vendor context, check the live vendor page, the batch-linked COA, the named lab, and any archived claim record.
Does this page provide medical advice?
No. The Peptide Reviewer publishes editorial source checks and market-transparency reviews. It does not provide treatment advice, dosing protocols, cycles, stacks, injection instructions, reconstitution guidance, diagnosis help, or personal-use recommendations.
Can affiliate relationships change the conclusion?
No. Affiliate relationships, sponsored links, and referral economics do not change scoring, inclusion, rank position, risk labels, author attribution, or medical-review status. Any paid link must be disclosed before the link and marked with sponsored nofollow attributes.
What happens if a source changes?
The page should be updated through the corrections process. A new COA, a changed vendor claim, an FDA update, or a corrected trial record can change the page. Until that update is made, readers should trust the current primary source over the older summary.
Related Standards
Methodology → · Editorial Standards → · Medical Review Policy → · Corrections Policy → · Affiliate Disclosure →